Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Nebivolol improves microvascular perfusion in skeletal muscle during exercise in hypertensive patients and whether this improvement is accompanied by reduction in vascular oxidative stress or increased endothelial nitric oxide synthase (eNOS) expression in humans.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Forest Laboratories
• Treatments: Hydrochlorothiazide; Metoprolol; Nebivolol; Nitric Oxide; Polystyrene sulfonic acid

Criteria

Inclusion Criteria:

• Men and women with stage I primary untreated hypertension (BP between 140-159/90-99 mmHg)

• Age 18-65

Exclusion Criteria:

• Congestive heart failure

• Coronary artery disease

• Left ventricular hypertrophy by echocardiography or ECG

• History of stroke

• Average blood pressure >159/99 mmHg

• Bradycardia with a resting heart rate <55 bpm

• Chronic kidney disease with a serum creatinine > 1.4 mg/dL

• Asthma or chronic obstructive pulmonary disease

• Women who are pregnant or planning to become pregnant

• Hypersensitivity to beta blockers, hydrochlorothiazide, or Definity

• Any history of substance abuse (other than tobacco)

• Concomitant drug treatment which raises endogenous nitric oxide levels, including nitrates or phosphodiesterase V inhibitors (Viagra, Levitra)

• History of symptomatic bradycardia or heart block

• Patients with Right-to-left, bidirectional, or transient right-to-left cardiac shunts

• Hypersensitivity to perflutren, blood, blood products or albumin.